Semaglutide once a week in adults with overweight or obesity, with or without type 2 diabetes in an east Asian population (STEP 6): a randomised, double-blind, double-dummy, placebo-controlled, phase 3a trial
Source : https://www.thelancet.com/journals/landia/article/PIIS2213-8587(22)00008-0/fulltext
Adults from east Asia with obesity, with or without type 2 diabetes, given semaglutide 2·4 mg once a week had superior and clinically meaningful reductions in bodyweight, and greater reductions in abdominal visceral fat area compared with placebo, representing a promising treatment option for weight management in this population.
Relevance: Adults from east Asia with obesity, with or without type 2 diabetes, given semaglutide 2·4 mg once a week had superior and clinically meaningful reductions in bodyweight, and greater reductions in abdominal visceral fat area compared with placebo, representing a promising treatment option for weight management in this population.
• Source: The Lancet Diabetes & Endocrinology
• Interpretation: “Adults from east Asia with obesity, with or without type 2 diabetes, given semaglutide 2.4 mg once a week had superior and clinically meaningful reductions in bodyweight, and greater reductions in abdominal visceral fat area compared with placebo, representing a promising treatment option for weight management in this population.”
• Asian and non-Asian populations differ with respect to body composition and definitions of obesity. In the Semaglutide Treatment Effect in People with obesity (STEP) 6 trial, investigators analyzed the outcomes of semaglutide versus placebo for weight management in adults from east Asia with obesity either with or without type 2 diabetes.
• In this randomized, double-blind, placebo-controlled trial, researchers assigned 401 patients to receive 2.4 mg, semaglutide 1.7 mg, or placebo.
• Mean bodyweight from baseline to week 68 was –13.2% in the semaglutide 2.4 mg group vs –9.6% in the semaglutide 1.7 mg group vs –2.1% in the placebo group. Gastrointestinal adverse effects occurred in 59% of patients and were mostly mild or moderate.